# Keros Therapeutics, Inc. Common Stock (KROS)

> Keros Therapeutics, Inc. Common Stock (KROS) trades at $11.08 (-2.72%) as of 4:25:24 PM EST on Nov 20, 2026, -2.56% over the past month. Market cap is $223.52M, with 7.1 days to cover in short interest.

Canonical: https://massive.com/quote/kros
Data as of: 2026-11-20T21:25:24.215Z (15-minute delayed)
Source: Massive (https://massive.com/docs/llms.txt)

## Price

**$11.08** -0.31 (-2.72%)
At close · 15-minute delayed
Nasdaq · usd

After hours: **$11.02** -0.06 (-0.54%)
As of 4:25:24 PM EST on Nov 20, 2026 · After hours

## Stock performance

How Keros Therapeutics, Inc. Common Stock (KROS) stock has performed from one day to one year, with its 52-week range.

| Period | Return |
| --- | --- |
| 1D | -2.90% |
| 1W | +7.38% |
| 1M | -2.56% |
| YTD | -45.68% |
| 1Y | -36.40% |
| 52-wk range | $8.98 – $22.55 |

From daily closes through Nov 20, 2026.

## Key statistics

Today's trading snapshot for KROS: day range, open, previous close, volume and market cap.

| Measure | Value |
| --- | --- |
| Day range | $10.95 – $11.59 |
| Open | $11.18 |
| Prev close | $11.39 |
| Volume | 208.69K |
| Market cap | $223.52M |
| Shares out | 19.62M |

## Valuation and profitability ratios

Valuation and profitability ratios for Keros Therapeutics, Inc. Common Stock: P/E, P/S, P/B, ROE and more.

| Measure | Value |
| --- | --- |
| P/E | — |
| P/S | 5.48 |
| P/B | 0.80 |
| P/FCF | — |
| ROE | -22.1% |
| ROA | -20.1% |
| Debt/Equity | 0.00 |
| Div yield | 0.00% |

As of Nov 19, 2026

## Insider trading

[Keros Therapeutics, Inc. Common Stock (KROS) insider trading](https://massive.com/quote/kros/insider-trading.md): open-market Form 4 buys and sells by Keros Therapeutics, Inc. Common Stock insiders over the last 12 months.

## 8-K filings

Material corporate events Keros Therapeutics, Inc. Common Stock has disclosed to the SEC on Form 8-K.

- Nov 16, 2026 · [Share repurchase program](https://massive.com/quote/sec-filings/8-k/share-buybacks.md)
  “On November 16, 2026, Keros Therapeutics, Inc. ... issued a press release announcing that the board of directors of the Company has approved a new stock repurchase program for up to $5 million of the Company's common stock.”
- Nov 5, 2026 · [Quarterly earnings](https://massive.com/quote/sec-filings/8-k/earnings-releases.md)
  “On November 5, 2026, Keros Therapeutics, Inc. (the "Company") issued a press release announcing its recent business highlights and financial results for the quarter ended September 30, 2026.”
- Nov 5, 2026 · Investor presentation
  “On November 5, 2026, Keros Therapeutics, Inc. (the "Company") updated its corporate presentation for use in meetings with investors, analysts and others. The presentation is available through the Company's website and a copy is attached as Exhibit 99.1 to this Current Report on Form 8-K.”
- Sep 29, 2026 · Licensing agreement
  “The Company will receive a $20 million development milestone payment under the terms of the license agreement of elritercept with partner Takeda Pharmaceuticals U.S.A., Inc.”
- Sep 8, 2026 · [Guidance issuance or update](https://massive.com/quote/sec-filings/8-k/guidance-updates.md)
  “Based on its current operating plans, the Company anticipates that its cash and cash equivalents as of June 30, 2026, after giving effect to (i) the $20 million development milestone received under the license agreement with Takeda and (ii) the Stock Repurchase, will be sufficient to enable it to fund its operating expenses and capital expenditure requirements into the second half of 2028.”

## KROS short interest

How heavily KROS is shorted: shares short, days to cover and average daily volume.

| Measure | Value |
| --- | --- |
| Days to cover | 7.1 |
| Short interest | 1.09M |
| Avg volume | 153.86K |

As of Oct 30, 2026 · reported to FINRA twice monthly.

## KROS news

The latest news and headlines about Keros Therapeutics, Inc. Common Stock (KROS).

- [What Makes Keros Therapeutics (KROS) a New Strong Buy Stock](https://www.zacks.com/stock/news/3032699/what-makes-keros-therapeutics-kros-a-new-strong-buy-stock?cid=CS-ZC-FT-fundamental_analysis|yseop_template_12_zacks_rank_upgrade-3032699) · Zacks Investment Research · Nov 19, 2026 · positive sentiment
- [Best Momentum Stocks to Buy for November 19th](https://www.zacks.com/commentary/3032161/best-momentum-stocks-to-buy-for-november-19th?cid=CS-ZC-FT-zacks_1_rank_additions|momentum_additions-3032161) · Zacks Investment Research · Nov 19, 2026 · positive sentiment
- [Wall Street Analysts Predict a 57.17% Upside in Keros Therapeutics (KROS): Here's What You Should Know](https://www.zacks.com/stock/news/3032506/wall-street-analysts-predict-a-57-17-upside-in-keros-therapeutics-kros-here-s-what-you-should-know?cid=CS-ZC-FT-fundamental_analysis|consensus_price_target-3032506) · Zacks Investment Research · Nov 19, 2026 · positive sentiment
- [New Strong Buy Stocks for November 19th](https://www.zacks.com/commentary/3031488/new-strong-buy-stocks-for-november-19th?cid=CS-ZC-FT-zacks_1_rank_additions-3031488) · Zacks Investment Research · Nov 19, 2026 · positive sentiment
- [Keros Therapeutics, Inc. (KROS) Q3 Earnings and Revenues Surpass Estimates](https://www.zacks.com/stock/news/3024885/keros-therapeutics-inc-kros-q3-earnings-and-revenues-surpass-estimates?cid=CS-ZC-FT-fundamental_analysis|yseop_template_4-3024885) · Zacks Investment Research · Nov 5, 2026 · neutral sentiment

## About Keros Therapeutics, Inc. Common Stock

Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.

| Measure | Value |
| --- | --- |
| Exchange | Nasdaq |
| Market | stocks |
| Type | CS |
| Currency | USD |
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 92 |
| Listed | Apr 8, 2020 |

[Company website](https://www.kerostx.com)

## FAQ

### What is the Keros Therapeutics, Inc. Common Stock (KROS) stock price today?

Keros Therapeutics, Inc. Common Stock (KROS) is trading at $11.08 (-2.72% on the day) as of 4:25:24 PM EST on Nov 20, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

### What is Keros Therapeutics, Inc. Common Stock?

Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs.

### What is the short interest in KROS?

As of Oct 30, 2026, KROS has 1.09M shares short and 7.1 days to cover.

### What exchange is KROS listed on?

Keros Therapeutics, Inc. Common Stock (KROS) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.

## Live data

Prices here are 15-minute delayed. For real-time KROS quotes and the full history behind this page, use the Massive API or MCP server:

- `GET https://api.massive.com/v3/snapshot?ticker.any_of=KROS`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [Keros Therapeutics, Inc. Common Stock (KROS) insider trading](https://massive.com/quote/kros/insider-trading.md)
- [SEC 8-K events](https://massive.com/quote/sec-filings/8-k.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms
